NYSEARCA:XBI SPDR S&P Biotech ETF (XBI) Price, Holdings, & News $83.92 +0.78 (+0.94%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$82.94▼$85.5050-Day Range$73.13▼$87.5552-Week Range$62.13▼$95.18Volume6.20 million shsAverage Volume8.91 million shsMarket Capitalization$6.79 billionAssets Under Management$6.43 billionDividend Yield0.00%Net Expense Ratio0.35% ProfileProfileChartHeadlinesHoldingsOptions ChainProfileChartHeadlinesHoldingsOptions Chain About SPDR S&P Biotech ETF (NYSEARCA:XBI)SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.Read More Receive XBI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SPDR S&P Biotech ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address XBI ETF News HeadlinesMay 26, 2023 | ca.finance.yahoo.comXBI - SPDR S&P Biotech ETFMay 18, 2023 | americanbankingnews.comSPDR S&P Biotech ETF (NYSEARCA:XBI) Sees Large Volume IncreaseMay 31, 2023 | Edge On The Street (Ad)Soaring EV Industry Keeps Investor Focus on LithiumThe need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.May 15, 2023 | msn.comBiotech ETF XBI jumps to a 3-month trading highMay 10, 2023 | realmoney.thestreet.comTake a Look Under the Microscope at These Two Biopharma StocksMay 5, 2023 | msn.comPro Stock of the Week: Vertex Pharmaceuticals to Pave the Way for Biotech ReboundMay 5, 2023 | americanbankingnews.comSPDR S&P Biotech ETF Target of Unusually Large Options Trading (NYSEARCA:XBI)May 3, 2023 | msn.comBiotech Stocks Are Heavily Shorted. They Could Be Winners.May 31, 2023 | Edge On The Street (Ad)Soaring EV Industry Keeps Investor Focus on LithiumThe need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.May 2, 2023 | msn.comUnusual Put Option Trade in SPDR S&P Biotech ETF (XBI) Worth $290.18KSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive XBI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SPDR S&P Biotech ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerSSgA Fund NameSPDR S&P Biotech ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:XBI Inception Date1/31/2006 Fund ManagerMichael Feehily, Karl Schneider, Raymond Donofrio Webwww.spdrs.com Phone+1-866-7872257Fund Focus Asset ClassEquity BenchmarkS&P Biotech Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings151 Fund Statistics Assets Under Management$6.43 billion Average Daily Volume$10.20 million Discount/Premium-0.07% Administrator, Advisor and Custodian AdministratorSSgA Funds Management, Inc. AdvisorSSgA Funds Management, Inc. CustodianState Street Bank and Trust Company DistributorState Street Global Advisors Funds Distributors, LLC Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerVirtu Financial Options OptionableOptionable Options Volume36,041 Put Options15,051 Call Options20,990 Short Interest38,380,000 shs Miscellaneous Outstanding Shares80,880,000Beta0.97 Creation Unit50,000 Creation Fee$250.00 SPDR S&P Biotech ETF ExpensesTypeXBIHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.35%0.54%0.52%0.50%0.49%Other Expenses0.00%0.41%0.48%0.64%0.51%Total Expense0.35%0.69%0.67%0.74%0.66%Fee Waiver0.00%-0.39%-0.49%-0.70%-0.52%Net Expense0.35%0.60%0.58%0.57%0.55% SPDR S&P Biotech ETF (XBI) Holdings & ExposureTop 10 XBI HoldingsTG Therapeutics(NASDAQ:TGTX)Holding Weight: 1.63%Prometheus Biosciences(NASDAQ:RXDX)Holding Weight: 1.57%Viking Therapeutics(NASDAQ:VKTX)Holding Weight: 1.57%IVERIC bio(NASDAQ:ISEE)Holding Weight: 1.41%Apellis Pharmaceuticals(NASDAQ:APLS)Holding Weight: 1.24%Arrowhead Pharmaceuticals(NASDAQ:ARWR)Holding Weight: 1.24%Madrigal Pharmaceuticals(NASDAQ:MDGL)Holding Weight: 1.19%Fate Therapeutics(NASDAQ:FATE)Holding Weight: 1.15%PTC Therapeutics(NASDAQ:PTCT)Holding Weight: 1.15%Blueprint Medicines(NASDAQ:BPMC)Holding Weight: 1.12%XBI Sector ExposureXBI Industry ExposureFull Holdings Details Key ExecutivesJames E. Ross (Age 52)President, Trustee Peter A. Ambrosini (Age 69)Chief Compliance Officer Michael P. Riley (Age 44)Vice President Gary L. French (Age 64)Treasurer John W. Clark (Age 46)Assistant Treasurer Matthew W. Flaherty (Age 42)Assistant Treasurer Chad C. Hallett (Age 47)Assistant Treasurer of Street tracks series trust Mary Moran Zeven (Age 52)Secretary Scott M. Zoltowski (Age 44)Assistant Secretary Dave KellyIndependent TrusteeMore ExecutivesSimilar ETFsiShares U.S. Medical Devices ETFNYSEARCA:IHIiShares Biotechnology ETFNASDAQ:IBBiShares Global Healthcare ETFNYSEARCA:IXJiShares U.S. Healthcare ETFNYSEARCA:IYHFidelity MSCI Health Care Index ETFNYSEARCA:FHLCInstitutional OwnershipEmpower Advisory Group LLCBought 2,701 shares on 5/25/2023Ownership: 0.003%Verity Asset Management Inc.Bought 782 shares on 5/24/2023Ownership: 0.019%Ameriprise Financial Inc.Sold 130,863 shares on 5/22/2023Ownership: 0.652%Arete Wealth Advisors LLCBought 7,001 shares on 5/22/2023Ownership: 0.009%Courier Capital LLCSold 850 shares on 5/18/2023Ownership: 0.027%View All Institutional Transactions XBI ETF - Frequently Asked Questions How have XBI shares performed in 2023? SPDR S&P Biotech ETF's stock was trading at $83.00 at the start of the year. Since then, XBI shares have increased by 1.4% and is now trading at $84.13. View the best growth stocks for 2023 here. What does XBI invest in? SPDR S&P Biotech ETF is a equity fund issued by SSgA. XBI focuses on health care investments and follows the S&P Biotech Index. The fund's investments total to approximately $6.43 billion assets under management. What stocks does SPDR S&P Biotech ETF hold? XBI invests in 151 holdings. Some of the stocks in their portfolio include TG Therapeutics (TGTX), Prometheus Biosciences (RXDX), Viking Therapeutics (VKTX), IVERIC bio (ISEE), Apellis Pharmaceuticals (APLS), Arrowhead Pharmaceuticals (ARWR), Madrigal Pharmaceuticals (MDGL), Fate Therapeutics (FATE), PTC Therapeutics (PTCT) and Blueprint Medicines (BPMC). What is the management fee for SPDR S&P Biotech ETF? SPDR S&P Biotech ETF's management fee is 0.35% and has no other recorded expenses or fee waivers. The net expense ratio for XBI is 0.35%. What other stocks do shareholders of SPDR S&P Biotech ETF own? Based on aggregate information from My MarketBeat watchlists, some companies that other SPDR S&P Biotech ETF investors own include Intel (INTC), NVIDIA (NVDA), Pfizer (PFE), Gilead Sciences (GILD), iShares Biotechnology ETF (IBB), Walt Disney (DIS), Micron Technology (MU), Cisco Systems (CSCO), AbbVie (ABBV) and Netflix (NFLX). What is SPDR S&P Biotech ETF's stock symbol? SPDR S&P Biotech ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "XBI." Who are SPDR S&P Biotech ETF's major shareholders? SPDR S&P Biotech ETF's stock is owned by a variety of retail and institutional investors. Top institutional investors include JPMorgan Chase & Co. (9.32%), Susquehanna International Group LLP (0.00%), Proficio Capital Partners LLC (2.95%), Brown Advisory Inc. (2.37%), Suvretta Capital Management LLC (0.00%) and Two Sigma Advisers LP (2.15%). How do I buy shares of SPDR S&P Biotech ETF? Shares of XBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is SPDR S&P Biotech ETF's stock price today? One share of XBI stock can currently be purchased for approximately $84.13. How much money does SPDR S&P Biotech ETF make? SPDR S&P Biotech ETF (NYSEARCA:XBI) has a market capitalization of $6.80 billion. How can I contact SPDR S&P Biotech ETF? SPDR S&P Biotech ETF's mailing address is One Lincoln Street, Boston, 02111, United States. The official website for the company is www.spdrs.com. The exchange traded fund can be reached via phone at +1-866-7872257. This page (NYSEARCA:XBI) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Biotech ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.